Rubicon Research Ltd — earnings calls

Rubicon Research reported Q1 FY27 revenue from operations of INR534 crores, EBITDA of INR131 crores, and PAT of around INR85 crores, representing year-on-year growth of 51%, 65%, and over 95% respectively. The quarter included the first consolidation impact of the Arinna Lifesciences acquisition, which contributed roughly INR12 crores to revenue with no material EBITDA impact. Management also announced the acquisition of a manufacturing facility in New Jersey, USA, progress on FDA compliance at the Pithampur site, and a leadership transition in which the CFO will move to a Chief Commercial Officer role.

Rubicon Research reported Q4 FY26 revenue of INR5,139-5,140 million, up 44% year-on-year, with EBITDA of INR1,190-1,213 million and PAT growth of 111-112% for the quarter. Management attributed growth to broad-based demand across established products and new launches, and described a slight decline in gross margin due to increased reliance on outsourced manufacturing while the Pithampur facility awaits FDA inspection. The company also disclosed the acquisition of an 85% stake in Arinna Lifesciences to build a CNS platform in the Indian market, and the board recommended a dividend of 150% (INR1.5 per share).